Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Donation - Other Level

Please use the quantity box to donate any amount you wish. Sign Up to Donate

Contact

Send a question or comment using the form below. This message may be routed through support staff.

Email Article

Password Reset Request

Register


Add a topic or expert to your feed.

Following

Follow Experts & Topics

Stay on top of our work by selecting topics and experts of interest.

Experts
Topics
Project
On The Ground
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed

Manhattan Institute

search
Close Nav
Share this commentary on Close

How Can Policymakers Bridge the Gap Between Precision Medicine and FDA Regulation?

commentary

How Can Policymakers Bridge the Gap Between Precision Medicine and FDA Regulation?

Forbes August 19, 2015
Health PolicyFDA Reform

Peter Huber and Paul Howard of the Manhattan Institute for Policy Research analyze the disjuncture between biomarker science, which has tremendous potential for catalyzing precision medicine, and FDA’s current capacity to incorporate biomarkers into the regulatory procedures for drug approval. The authors argue that FDA policy is significantly stalling the development of important drugs, and offer recommendations for developing and implementing evidentiary standards that can expedite review and approval of biomarkers for drug development.

This piece originally appeared in Volume 5, issue 7 of Food and Drug Policy Forum, and requires paid-subscription to read.

Saved!
Close